The pharmaceutical company Gilead has announced that the price of their antiviral, used with modest results to treat COVID-19, will be 2083 Euros per patient when the minimum cost of production is 0.83 Euros per dose. The price of medicines should be related to the cost of development and production, plus a fair and reasonable profit, particularly in light of the public effort that has been invested in the R&D chain.
Control measures to overcome the COVID-19 pandemic affect different population sectors in radically different ways. In the current, almost dystopian situation, social determinants of health are more clearly shown.
Virologist Luis Enjuanes, Spain's foremost expert on coronaviruses, , is working non-stop. From his laboratory at the CSIC's National Centre for Biotechnology, he is engaged in trying to find, in the shortest time possible, a vaccine to stop the COVID-19 epidemic.
Lo sentimos, Inténtalo de nuevo más tarde. .
